Product Datasheet
|
Catalog Number |
ADT1090 |
|
Product Name |
Bevacizumab Research Biosimilar |
|
Product Description |
Transcription of the VEGF protein is induced by 'hypoxia inducible factor' in a hypoxic environment. When circulating VEGF binds to VEGF receptors located on endothelial cells, various downstream effects are initiated. It should be noted that VEGF also binds to the neuropilin co-receptors , leading to enhanced signaling. |
|
CAS Number |
216974-75-3 |
|
Chemical Formula |
C6638H10160N1720O2108S44 |
|
Clonity |
Monoclonal |
|
Target |
VEGFA[Homo sapiens] |
|
Alias |
12-IgG1, F(ab)-12 IgG1, Bevacizumab Research Biosimilar |
|
Species |
Human |
|
Host |
CHO Cells |
|
Isotype |
IgG1 Kappa |
|
Size |
1mg,5mg |
|
Molecular Weight |
149.15 KDa |
|
Metabolism |
There are several pathways through which monoclonal antibodies (mAbs) may be cleared. Non-specific clearance of mAbs refers to target independent pinocytosis, and proteolysis of the protein into small amino acids and peptides in the reticuloendothelial system (RES) and the liver. Target-mediated clearance is a result of specific interactions between the mAb and its target antigen. Once bound, the antibody-antigen complex may be cleared via lysosomal degradation. Additionally, the production of anti-drug antibodies (ADA), which are a result of an immunogenic response to mAb-based treatment, can form complexes with mAb’s and may impact the rate of mAb clearance. |
|
Buffer |
Supplied in PBS, PH7.5 |
|
Concentration |
Batch dependent, please contact our customer service to get the COAs of current batch |
|
Purity |
>95% as determined by SDS-PAGE |
|
Storage |
Store at -20 °C for 12 months. Store at -80 °C for long term storage. |
|
Shipping Condition |
This product is shipped in blue ice. |
.jpg){kind=logo}
